Remdesivir Efficacy in Coronavirus Disease

Phase 2

Completed

• Conditions: COVID
• Interventions: Other: Standard of care treatment; Drug: Remdesivir

• Registration Number: NCT04345419
• Lead Sponsor: Tanta University

Brief Summary

COVID 19 treatment using Remedesvir.

Detailed Description

COVID 19 treatment using Remedesvir. Is this drug effective?

Study Timeline

• Study First Submitted: 2020-04-11
• Study First Submitted QC: 2020-04-13
• Study First Posted: 2020-04-14
• Study Start: 2020-06-16
• Primary Completion: 2020-12-01
• Study Completion: 2020-12-01
• Status Verified: 2021-07
• Last Update Submitted: 2021-07-29
• Last Update Posted: 2021-08-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• COVID 19 patients

Exclusion Criteria

• allergy or contraindication to the drug

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Standard of care	Standard of care treatment	Standard of care treatment alone.
Remdesivir	Standard of care treatment	Remdesivir with standard of care treatment standard of care treatment
Remdesivir	Remdesivir	Remdesivir with standard of care treatment standard of care treatment

Primary Outcome Measures

Name	Time	Method
Number of patients with improvement or mortality	6 months	the estimated number of patients with improvement or mortality

Trial Locations

Locations (1)

Tanta university hospital, Assuit University, Ainshams University; 🇪🇬 Tanta, Egypt